Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B

The New England Journal of Medicine
Patrick MarcellinPeginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group

Abstract

Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications. We compared the efficacy and safety of peginterferon alfa-2a (180 microg once weekly) plus placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively. Patients were treated for 48 weeks and followed for an additional 24 weeks. After 24 weeks of follow-up, the percentage of patients with normalization of alanine aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003, respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained suppression of HBV DNA to below 400 copies per milliliter were 19 percent with peginterfer...Continue Reading

References

May 1, 1986·Gastroenterology·F BoninoG Verme
Jun 1, 1995·Journal of Hepatology·K IshakR N MacSween
Jul 27, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Y F LiawC M Chu
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S J HadziyannisC Papaioannou
Sep 26, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·D D Richman
Dec 7, 2000·The New England Journal of Medicine·S ZeuzemM J Brunda
Oct 5, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S J Hadziyannis, D Vassilopoulos
Oct 27, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S Nair, R P Perrillo
Apr 12, 2002·Journal of Hepatology·Michelle Martinot-PeignouxPatrick Marcellin
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
Feb 27, 2003·Journal of Gastroenterology and Hepatology·Yun-Fan LiawUNKNOWN Asian-Pacific Consensus Working Parties on Hepatitis B
Feb 28, 2003·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Mar 5, 2003·Journal of Viral Hepatitis·D M FortonH C Thomas
Apr 2, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Pietro LamperticoMassimo Colombo
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chi-Jen ChuUNKNOWN U.S. HBV Epidemiology Study Group
Dec 31, 2003·Lancet·Ching Lung LaiThierry Poynard
Mar 5, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F LokUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD)

❮ Previous
Next ❯

Citations

Mar 29, 2006·Journal of Gastroenterology·Takeshi Okanoue, Masahito Minami
Jul 21, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Mehlika ToyCihan Yurdaydin
Aug 29, 2006·Wiener medizinische Wochenschrift·Christian Müller
Jan 5, 2011·Journal of General Internal Medicine·Tatyana A ShamliyanTimothy J Wilt
Mar 6, 2007·Current Gastroenterology Reports·Robert G Gish
Jan 27, 2009·Current Gastroenterology Reports·Anil Seetharam, Mauricio Lisker-Melman
Jan 27, 2009·Current Gastroenterology Reports·John D Scott, Brian McMahon
Aug 11, 2005·Current HIV/AIDS Reports·Marion G Peters
May 31, 2008·Current HIV/AIDS Reports·Vincent SorianoPablo Barreiro
Aug 25, 2009·Current Infectious Disease Reports·Melissa Osborn
Nov 6, 2004·Current Treatment Options in Gastroenterology·Stephanie D Straley, Norah A Terrault
Jan 29, 2008·Current Treatment Options in Gastroenterology·Chee-Kin Hui, George K Lau
Jun 1, 2008·Hepatology International·Teerha Piratvisuth
Aug 12, 2009·Hepatology International·Yock Young DanSeng Gee Lim
Aug 12, 2009·Hepatology International·Yun-Fan LiawUNKNOWN Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver
Mar 23, 2010·Hepatology International·Sang Hoon AhnUNKNOWN APPROACH Working Group
Apr 13, 2011·Hepatology International·Daniel GrimmHubert E Blum
Aug 13, 2013·Hepatology International·Hamad I Al-AshgarKhalid I Bzeizi
Jun 1, 2012·Hepatology International·Yun-Fan LiawMasao Omata
Feb 20, 2009·Advances in Therapy·Kathryn Nash
Mar 11, 2005·Best Practice & Research. Clinical Gastroenterology·Hubert E Blum
May 28, 2005·The Lancet Infectious Diseases·Marina Núñez, Vincent Soriano
Jun 25, 2010·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Yun-Fan Liaw
Nov 3, 2005·Nature Clinical Practice. Gastroenterology & Hepatology·Graham Cooksley
Aug 3, 2006·Nature Clinical Practice. Gastroenterology & Hepatology·Smruti R MohantyVijay Khiani
Dec 1, 2007·Nature Reviews. Drug Discovery·Ernest C BordenGeorge R Stark
Jul 8, 2009·Nature Reviews. Gastroenterology & Hepatology·Watcharasak Chotiyaputta, Anna S F Lok
Mar 23, 2011·Nature Reviews. Gastroenterology & Hepatology·Hellan Kwon, Anna S Lok
Nov 14, 2012·Nature Reviews. Gastroenterology & Hepatology·Augusto VillanuevaJosep M Llovet
Dec 31, 2004·The New England Journal of Medicine·Matthew Cockerill, Jan Velterop
Jul 1, 2005·The New England Journal of Medicine·Anna Suk-Fong Lok
Mar 10, 2006·The New England Journal of Medicine·Jay H Hoofnagle
Jul 1, 2005·The New England Journal of Medicine·Stephanos J HadziyannisUNKNOWN Adefovir Dipivoxil 438 Study Group
Jul 1, 2005·The New England Journal of Medicine·George K K LauUNKNOWN Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
Mar 10, 2006·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN BEHoLD AI463027 Study Group
Dec 21, 2007·The New England Journal of Medicine·Ching-Lung LaiUNKNOWN Globe Study Group
Jan 28, 2011·The New England Journal of Medicine·Heiner WedemeyerUNKNOWN HIDIT Study Group
Apr 6, 2007·The New England Journal of Medicine·Margaret James Koziel, Marion G Peters
Oct 4, 2008·The New England Journal of Medicine·Jules L Dienstag
Oct 26, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Hua TanLawrence M Blatt
May 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mark H EckmanKenneth E Sherman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

The New England Journal of Medicine
George K K LauPeginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group
The New England Journal of Medicine
Ting-Tsung ChangBEHoLD AI463022 Study Group
The New England Journal of Medicine
Stephanos HadziyannisAdefovir Dipivoxil 438 Study Group
© 2021 Meta ULC. All rights reserved